Hemopressin is an inverse agonist of CB 1 cannabinoid receptors
- 18 December 2007
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 104 (51), 20588-20593
- https://doi.org/10.1073/pnas.0706980105
Abstract
To date, the endogenous ligands described for cannabinoid receptors have been derived from membrane lipids. To identify a peptide ligand for CB1 cannabinoid receptors, we used the recently described conformation-state sensitive antibodies and screened a panel of endogenous peptides from rodent brain or adipose tissue. This led to the identification of hemopressin (PVNFKFLSH) as a peptide ligand that selectively binds CB1 cannabinoid receptors. We find that hemopressin is a CB1 receptor-selective antagonist, because it is able to efficiently block signaling by CB1 receptors but not by other members of family A G protein-coupled receptors (including the closely related CB2 receptors). Hemopressin also behaves as an inverse agonist of CB1 receptors, because it is able to block the constitutive activity of these receptors to the same extent as its well characterized antagonist, rimonabant. Finally, we examine the activity of hemopressin in vivo using different models of pain and find that it exhibits antinociceptive effects when administered by either intrathecal, intraplantar, or oral routes, underscoring hemopressin's therapeutic potential. These results represent a demonstration of a peptide ligand for CB1 cannabinoid receptors that also exhibits analgesic properties. These findings are likely to have a profound impact on the development of novel therapeutics targeting CB1 receptors.Keywords
This publication has 42 references indexed in Scilit:
- Targeting cannabinoid agonists for inflammatory and neuropathic painExpert Opinion on Investigational Drugs, 2007
- Effect of the cannabinoid CB1 receptor antagonist rimonabant on nociceptive responses and adjuvant‐induced arthritis in obese and lean ratsBritish Journal of Pharmacology, 2007
- Endocannabinoid mechanisms of pain modulationThe AAPS Journal, 2006
- The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurinProceedings of the National Academy of Sciences, 2006
- Identification and Functional Characterization of Brainstem Cannabinoid CB 2 ReceptorsScience, 2005
- Cannabinoid Receptor-induced Neurite Outgrowth Is Mediated by Rap1 Activation through Gαo/i-triggered Proteasomal Degradation of Rap1GAPIIPublished by Elsevier BV ,2005
- ACE gene titration in mice uncovers a new mechanism for ACE on the control of body weightPhysiological Genomics, 2005
- Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain modelsEuropean Journal of Neuroscience, 2003
- Cannabinoid analgesiaPharmacology & Therapeutics, 2002
- Ethical guidelines for investigations of experimental pain in conscious animalsPain, 1983